$ALMR

Alamar Biosciences (Nasdaq: ALMR) announced the launch of its NULISAseq Immune 340 Panel, expanding its NULISAseq Inflammation Panel 250 to measure about 340 immune-related proteins from a single sample. The company says the panel targets low-abundance proteins and regulatory markers, supporting translational research and drug development across cancer, cardiovascular, metabolic, autoimmune, and aging.

Alamar Biosciences (ALMR) shares rose 7.3% to a 52-week high of $28.42 after the company said its NULISA platform will be featured in more than 140 presentations at the Alzheimer’s Association International Conference, according to the company. The article notes no earnings or analyst action and contrasts weaker moves at peers like TMO and ILMN.

Biotech stocks hit 52-week highs on July 14, 2026. Hemab Therapeutics (COAG) reached $42.03 after positive Phase 2 results for HMB-002 and launched HMB-003. Alamar Biosciences (ALMR) hit $29.43 on a U.S. university proteomics partnership. Progyny (PGNY) rose 4% to $32; 2026 revenue guidance $1.365B-$1.405B. 10x Genomics (TXG) closed $43.98; 2026 revenue $600M-$625M. Viemed (VMD) peaked $12.61; 2026 net revenue $312M-$320M.

Alamar Biosciences (ALMR) said it will partner with U.S. research universities to profile blood biomarkers for Alzheimer’s and related neurodegenerative diseases. The initiative will analyze plasma from about 21,000 samples from 10,000 participants, using Alamar’s NULISAseq Neuro220 panel with an added eMTBR-Tau assay. ALMR shares closed at $28.42 on July 10, 2026.

Alamar Biosciences (Nasdaq: ALMR) said it will partner with research universities to launch a national proteomics initiative for Alzheimer’s and related dementias. It will profile about 21,000 plasma samples from 10,000 ADRD participants using its NULISAseq Neuro 220 panel, including an eMTBR-Tau assay, with data linked to NACC IDs and made publicly accessible.

Alamar Biosciences (Nasdaq: ALMR) said its NULISA platform will be featured in more than 140 poster and session presentations at AAIC 2026 in London (July 12-15). The company plans a workshop on July 14 highlighting new eMTBR-Tau and BD-pTau217 data, including results from a single NULISAseq panel measuring these assays alongside 220+ proteins.

Alamar Biosciences (Nasdaq: ALMR) said its NULISA platform data will be featured in more than 140 poster and session presentations at the Alzheimer’s Association International Conference (AAIC) in London July 12-15. The company will host a workshop on July 14 highlighting eMTBR-Tau and BD-pTau217 assays measured on a single NULISAseq panel with 220+ proteins, and claims improved discrimination versus pTau-217 alone.

Alamar Biosciences (Nasdaq: ALMR) launched a commercial eMTBR-Tau blood immunoassay for Alzheimer’s disease. The assay is available in the NULISAseq Neuro 220 multiplex panel for ARGO HT instruments and as a single-plex option via its Technology Access Program. Alamar says it targets tau tangle pathology and is planned for presentation at AAIC 2026.

Alamar Biosciences (Nasdaq: ALMR) launched a commercial blood-based eMTBR-Tau immunoassay for Alzheimer’s disease. The assay is available in the NULISAseq Neuro 220 multiplex panel for use on Alamar’s ARGO HT instruments and as a single-plex via its Technology Access Program. Alamar plans to present related performance and clinical data at AAIC 2026.